These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
133 related articles for article (PubMed ID: 23413900)
1. Role of the crosstalk between CTLA-4 and NKG2D in the development of anti-CTLA-4 treatment strategies. Demaria S; Dustin ML Immunotherapy; 2013 Feb; 5(2):109-12. PubMed ID: 23413900 [No Abstract] [Full Text] [Related]
2. Breakthrough of the year 2013. Cancer immunotherapy. Couzin-Frankel J Science; 2013 Dec; 342(6165):1432-3. PubMed ID: 24357284 [No Abstract] [Full Text] [Related]
3. Cancer Immunotherapy Researchers Focus on Refining Checkpoint Blockade Therapies. Jacob JA JAMA; 2015 Nov; 314(20):2117-9. PubMed ID: 26599172 [No Abstract] [Full Text] [Related]
4. NKG2D and its ligands. Obeidy P; Sharland AF Int J Biochem Cell Biol; 2009 Dec; 41(12):2364-7. PubMed ID: 19631280 [TBL] [Abstract][Full Text] [Related]
5. Cocktails for cancer with a measure of immunotherapy. Ledford H Nature; 2016 Apr; 532(7598):162-4. PubMed ID: 27075078 [No Abstract] [Full Text] [Related]
6. Suppressing T cell motility induced by anti-CTLA-4 monotherapy improves antitumor effects. Ruocco MG; Pilones KA; Kawashima N; Cammer M; Huang J; Babb JS; Liu M; Formenti SC; Dustin ML; Demaria S J Clin Invest; 2012 Oct; 122(10):3718-30. PubMed ID: 22945631 [TBL] [Abstract][Full Text] [Related]
7. NKG2D signaling in cancer immunosurveillance. López-Soto A; Huergo-Zapico L; Acebes-Huerta A; Villa-Alvarez M; Gonzalez S Int J Cancer; 2015 Apr; 136(8):1741-50. PubMed ID: 24615398 [TBL] [Abstract][Full Text] [Related]
8. Releasing the Brakes on Cancer Immunotherapy. Ribas A N Engl J Med; 2015 Oct; 373(16):1490-2. PubMed ID: 26348216 [No Abstract] [Full Text] [Related]
10. Targeted cancer immunotherapy with oncolytic adenovirus coding for a fully human monoclonal antibody specific for CTLA-4. Dias JD; Hemminki O; Diaconu I; Hirvinen M; Bonetti A; Guse K; Escutenaire S; Kanerva A; Pesonen S; Löskog A; Cerullo V; Hemminki A Gene Ther; 2012 Oct; 19(10):988-98. PubMed ID: 22071969 [TBL] [Abstract][Full Text] [Related]
11. [The role of co-inhibitory signals driven by CTLA-4 in immune system]. Olive D; le Thi S; Xerri L; Hirsch I; Nunès JA Med Sci (Paris); 2011 Oct; 27(10):842-9. PubMed ID: 22027421 [TBL] [Abstract][Full Text] [Related]
12. Molecular Pathways: Oncologic Pathways and Their Role in T-cell Exclusion and Immune Evasion-A New Role for the AXL Receptor Tyrosine Kinase. Aguilera TA; Giaccia AJ Clin Cancer Res; 2017 Jun; 23(12):2928-2933. PubMed ID: 28289089 [TBL] [Abstract][Full Text] [Related]
13. Cancer immunotherapy using NKG2D and DNAM-1 systems. Morisaki T; Onishi H; Katano M Anticancer Res; 2012 Jun; 32(6):2241-7. PubMed ID: 22641658 [TBL] [Abstract][Full Text] [Related]
20. Seminal immunologic discoveries with direct clinical implications: The 2018 Nobel Prize in Physiology or Medicine honours discoveries in cancer immunotherapy. Ljunggren HG; Jonsson R; Höglund P Scand J Immunol; 2018 Dec; 88(6):e12731. PubMed ID: 30485497 [No Abstract] [Full Text] [Related] [Next] [New Search]